Cargando…

Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence

INTRODUCTION: Alcohol dependence (AD) is associated with a dysregulated mesolimbocortical dopamine system—a pathway which is also implicated in both reward and cognition. The monoamine stabilizer (-)-OSU6162 (OSU) is a novel pharmacological compound with the ability to reduce ethanol intake and etha...

Descripción completa

Detalles Bibliográficos
Autores principales: Khemiri, Lotfi, Steensland, Pia, Guterstam, Joar, de Manzano, Örjan, Franck, Johan, Jayaram-Lindström, Nitya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952337/
https://www.ncbi.nlm.nih.gov/pubmed/31628507
http://dx.doi.org/10.1007/s00213-019-05345-6
_version_ 1783486427924791296
author Khemiri, Lotfi
Steensland, Pia
Guterstam, Joar
de Manzano, Örjan
Franck, Johan
Jayaram-Lindström, Nitya
author_facet Khemiri, Lotfi
Steensland, Pia
Guterstam, Joar
de Manzano, Örjan
Franck, Johan
Jayaram-Lindström, Nitya
author_sort Khemiri, Lotfi
collection PubMed
description INTRODUCTION: Alcohol dependence (AD) is associated with a dysregulated mesolimbocortical dopamine system—a pathway which is also implicated in both reward and cognition. The monoamine stabilizer (-)-OSU6162 (OSU) is a novel pharmacological compound with the ability to reduce ethanol intake and ethanol seeking in long-term drinking rats as well as reducing alcohol craving in AD patients. Dopaminergic drugs can both impair and improve cognitive functions, and the aim of the current study was to investigate the effect of OSU treatment on cognitive functioning in AD patients. METHOD: In a randomized double-blind placebo-controlled study, 56 individuals with AD received 14 days of OSU or placebo treatment. Neuropsychological tasks from the Cambridge Automated Neuropsychological Test Battery (CANTAB®) and other tasks were used to evaluate treatment effect on executive function/impulsivity, working memory, attention, emotional recognition, and divergent thinking. RESULTS: Treatment with OSU did not impair neuropsychological function in any of the cognitive domains investigated (all p > 0.1). In fact, OSU treatment did, compared to placebo, improve future planning ability (F((1,46)) = 6.9; p = 0.012; Cohen’s d = 0.54), verbal divergent thinking (F((1,44)) = 10.1; p = 0.003; d = 0.96), and response time for emotional recognition (F((1,47)) = 6.7; p = 0.013; d = 0.44). CONCLUSION: OSU treatment did not cause short-term cognitive side effects, further supporting the potential of OSU as a clinically feasible pharmacological treatment in AD patients. OSU treatment might improve future planning, verbal divergent thinking, and emotional recognition latency, which in turn may have a beneficial impact on alcohol use outcomes. Future studies are needed to confirm these preliminary findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00213-019-05345-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6952337
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-69523372020-01-23 Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence Khemiri, Lotfi Steensland, Pia Guterstam, Joar de Manzano, Örjan Franck, Johan Jayaram-Lindström, Nitya Psychopharmacology (Berl) Original Investigation INTRODUCTION: Alcohol dependence (AD) is associated with a dysregulated mesolimbocortical dopamine system—a pathway which is also implicated in both reward and cognition. The monoamine stabilizer (-)-OSU6162 (OSU) is a novel pharmacological compound with the ability to reduce ethanol intake and ethanol seeking in long-term drinking rats as well as reducing alcohol craving in AD patients. Dopaminergic drugs can both impair and improve cognitive functions, and the aim of the current study was to investigate the effect of OSU treatment on cognitive functioning in AD patients. METHOD: In a randomized double-blind placebo-controlled study, 56 individuals with AD received 14 days of OSU or placebo treatment. Neuropsychological tasks from the Cambridge Automated Neuropsychological Test Battery (CANTAB®) and other tasks were used to evaluate treatment effect on executive function/impulsivity, working memory, attention, emotional recognition, and divergent thinking. RESULTS: Treatment with OSU did not impair neuropsychological function in any of the cognitive domains investigated (all p > 0.1). In fact, OSU treatment did, compared to placebo, improve future planning ability (F((1,46)) = 6.9; p = 0.012; Cohen’s d = 0.54), verbal divergent thinking (F((1,44)) = 10.1; p = 0.003; d = 0.96), and response time for emotional recognition (F((1,47)) = 6.7; p = 0.013; d = 0.44). CONCLUSION: OSU treatment did not cause short-term cognitive side effects, further supporting the potential of OSU as a clinically feasible pharmacological treatment in AD patients. OSU treatment might improve future planning, verbal divergent thinking, and emotional recognition latency, which in turn may have a beneficial impact on alcohol use outcomes. Future studies are needed to confirm these preliminary findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00213-019-05345-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-10-18 2020 /pmc/articles/PMC6952337/ /pubmed/31628507 http://dx.doi.org/10.1007/s00213-019-05345-6 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Investigation
Khemiri, Lotfi
Steensland, Pia
Guterstam, Joar
de Manzano, Örjan
Franck, Johan
Jayaram-Lindström, Nitya
Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence
title Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence
title_full Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence
title_fullStr Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence
title_full_unstemmed Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence
title_short Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence
title_sort effects of the monoamine stabilizer (-)osu6162 on cognitive function in alcohol dependence
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952337/
https://www.ncbi.nlm.nih.gov/pubmed/31628507
http://dx.doi.org/10.1007/s00213-019-05345-6
work_keys_str_mv AT khemirilotfi effectsofthemonoaminestabilizerosu6162oncognitivefunctioninalcoholdependence
AT steenslandpia effectsofthemonoaminestabilizerosu6162oncognitivefunctioninalcoholdependence
AT guterstamjoar effectsofthemonoaminestabilizerosu6162oncognitivefunctioninalcoholdependence
AT demanzanoorjan effectsofthemonoaminestabilizerosu6162oncognitivefunctioninalcoholdependence
AT franckjohan effectsofthemonoaminestabilizerosu6162oncognitivefunctioninalcoholdependence
AT jayaramlindstromnitya effectsofthemonoaminestabilizerosu6162oncognitivefunctioninalcoholdependence